Sign in
Taking people in GermanyPhase 2

Tests ginisortamab with chemotherapy in advanced pancreatic cancer

Tests ginisortamab with chemotherapy in adults with advanced pancreatic cancer.

Key facts

Who runs it
Cancer Research UK
Where
Munich and Ulm, GermanySee the 2 sitesAlso in 2 other countries, 3 sites
Trial code
Registry title
A Phase II trial of ginisortamab in participants with metastatic pancreatic ductal adenocarcinoma
Status
Recruiting
Phase
Phase 2
People taking part
43 people, planned
Started
15 Jan 2025
Expected to end
1 Jun 2029
Type of study
Interventional
Record updated
21 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pancreatic cancer that has spread (metastatic pancreatic ductal adenocarcinoma). They take ginisortamab with standard chemotherapy, or as maintenance with cobimetinib.

Age
18 years or older
Sex
All sexes
Disease stage
Pancreatic ductal adenocarcinoma (PDAC) confirmed by tissue or cell tests, with metastatic disease and at least 1 measurable lesion. For Module 2: disease stable or responding after at least 16 weeks of standard first-line chemotherapy (FOLFIRINOX, or nab-paclitaxel plus gemcitabine), and not a candidate for PARP inhibitor maintenance.
Earlier treatment
Module 1: no prior chemotherapy for unresectable disease. Module 2: no more than one systemic chemotherapy regimen in the metastatic setting. No earlier investigational therapy for metastatic PDAC. No other anti-cancer treatment within 28 days or 5 half-lives (whichever is shorter) before the first dose.
Biomarker or test result
Tumour samples before and during treatment are needed to test markers such as SMAD4 and gremlin-1. Archival tissue up to 3 months old may be used if there is enough.

Main reasons for not taking part

  • Brain or leptomeningeal metastases
  • Neuroendocrine or acinar pancreatic cancer
  • Known HIV, hepatitis B or hepatitis C infection (some exceptions)
  • Immunodeficiency, immunosuppressive treatment (including systemic corticosteroids), or an organ transplant with immunosuppression
  • Significant heart or lung disease, or QTcF above 450 ms

The registry criteria, word for word

Show all 43 criteriaShow less

Who can take part

  • For all trial participants: Written (signed and dated) informed consent, and capable of co-operating with IMP (and AxMP, as applicable) administration and follow-up
  • For Module 2: Not a candidate for PARP inhibitor maintenance therapy
  • For all trial participants: Histologically or cytologically confirmed diagnosis of PDAC with metastatic disease
  • For all trial participants: Consent for pre- and on-treatment tumour biopsy samples for assessment of molecular markers, including, but not limited to, SMAD4 and gremlin-1. Pre- and on-treatment tumour samples are mandatory in the first instance*. These tumour samples may become optional as considered appropriate by the Sponsor and Investigators based on review of emerging data during the trial. Participants must have disease amenable to biopsy as deemed safe by the Investigator. If there is only 1 measurable lesion, then this should not be used for pre- and on-treatment biopsies and inclusion should be discussed with Sponsor. Archival tumour tissue can be used if adequate tissue for planned analysis is confirmed prior to trial inclusion. Archival tissue sample must be ≤3 months old, with no subsequent treatment and adequate tissue confirmed prior to trial inclusion. Please refer to the Study Laboratory Manual for details on assessment of adequacy of material. *on-treatment tumour samples are not required for participants randomised to Module 2 Expansion Arm B
  • For all trial participants: Measurable disease according to RECIST Version 1.1 (Appendix 2), with at least 1 measurable lesion (not in a previously irradiated area [for Module 1 only: unless radiological progression has occurred]) and not previously biopsied at screening
  • For all trial participants: ECOG performance status of ≤1 (to be confirmed at screening and within 7 days prior to Cycle 1 Day 1)
  • For all trial participants: Haematological and biochemical indices within the ranges shown in Protocol section 5.1.1, clause 6. These measurements should be performed to confirm the patient’s eligibility to participate in the trial
  • For all trial participants: Aged 18 years or over at the time consent is given
  • For Module 2: Investigator determination that the clinical interests of the participant are best served by stopping SoC induction therapy (FOLFIRINOX, or nab-paclitaxel plus gemcitabine) after attainment of a best response of ≥ SD
  • For Module 2: At least ongoing SD or response (CR/PR) after ≥16 weeks of treatment with a SoC first-line induction regimen (FOLFIRINOX, or nab-paclitaxel plus gemcitabine). Ongoing SD or response must be confirmed on the trial baseline scan

Who cannot take part

  • For all trial participants: Prior radiotherapy to the only measurable index lesion unless radiological progression has occurred following completion of radiotherapy
  • For all trial participants: Ongoing toxic manifestations of previous treatments considered by the Investigator to make the patient unsuitable for the trial
  • For all trial participants: Previous investigational therapy for the treatment of metastatic PDAC
  • For all trial participants: Previous concurrent anti-cancer treatment within 28 days or 5 half-lives (whichever is shorter) prior to Cycle 1 Day 1 (e.g., cytoreductive therapy, radiotherapy, immunotherapy, biologic therapy, or cytokine therapy [with the exception of erythropoietin])
  • For all trial participants: Live vaccinations will not be permitted within 28 days before trial enrolment or randomisation
  • For all trial participants: Prior neo-adjuvant, peri-operative, or adjuvant chemotherapy for non-metastatic pancreatic adenocarcinoma with curative intent unless recurrent (i.e. metastatic) disease is documented more than 6 months since the last dose of systemic therapy. Prior treatment with 5-FU, gemcitabine or capecitabine administered as a radiation sensitiser is allowed, provided that disease progression has occurred more than 6 months since completion of the last dose of chemotherapy or radiotherapy
  • For Module 1: Prior chemotherapy for unresectable disease
  • For Module 2: More than one systemic chemotherapy regimen given in the metastatic setting
  • For Module 2: Any strong inhibitors or inducers of CYP3A (including supplements) within 7 days prior to initiation of Cycle 1 Day 1, and during study treatment for participants in the safety runin and Expansion Arm A
  • For all trial participants: Major thoracic or abdominal surgery from which the patient has not yet recovered
  • For all trial participants: At high medical risk because of non-malignant systemic disease, including active uncontrolled infection. Patients with previous HCV exposure but no current infection are eligible to participate. Any uncontrolled active systemic infection requiring systemic IV treatment that was completed ≤7 days before Cycle 1 Day 1
  • For all trial participants: Radiotherapy (for non-metastatic disease) within the last 6 months prior to Cycle 1 Day 1 with the exception of palliative treatment (≤10 Gy single fraction or 25 Gy fractionated total) that has been completed at least 7 days prior to Cycle 1 Day 1
  • For all trial participants: Patients with any congenital or acquired immunodeficiency syndrome or who are receiving immunosuppressive therapy (including any dose of systemic corticosteroids), or who are immunosuppressed post-organ transplant. However, patients receiving inhaled corticosteroids and patients with a history of allergy (other than anaphylaxis) are eligible, as are patients with a history of autoimmune disease
  • For all trial participants: Any other condition that, in the Investigator’s opinion, would mean that the trial is not in the best interests of the patient
  • For all trial participants: Known to be serologically positive for HBV, HCV or HIV. Patients who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have an undetectable HCV RNA by PCR or HBV DNA (by PCR) that is <500 IU/mL before enrolment. Patients who are HBV core antibody positive should receive SoC antiviral therapy during trial treatment
  • For Module 2: Clinically significant ophthalmoscopic findings at the time of screening or history of ophthalmological findings, such as retinal detachment, severe visual impairment, central serous chorioretinopathy, neovascular retinopathy, or retinopathy of prematurity
  • For Module 2: History of retinal vein occlusion
  • For Module 2: Participant is unable to swallow cobimetinib intact, without chewing or crushing the tablets (as per the dosing schedule) or is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally
  • For all trial participants: Known hypersensitivity to any of the ingredients/excipients in the IMP/s to be administered
  • For all trial participants: Clinically significant ongoing pulmonary disease, including but not limited to interstitial lung disease, idiopathic pulmonary fibrosis or pulmonary hypersensitivity pneumonitis
  • For all trial participants: History of pulmonary embolism or deep vein thrombosis unless continuing anticoagulant treatment as clinically indicated
  • For all trial participants: Significant cardiovascular disease, as outlined in Protocol section 5.1.3 clause 17
  • For all trial participants: Current or prior malignancy that could affect safety or efficacy assessment of the IMP or compliance with the protocol or interpretation of results. Patients with curatively treated non-melanoma skin cancer, non-muscle-invasive bladder cancer, or carcinomas-in-situ are generally eligible. Patients with asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy, or who require only hormonal therapy and have had normal prostate-specific antigen for >1 year prior to the start of therapy, are eligible for participation in the trial
  • For Module 2: LVEF <40%. This measurement should be performed to confirm the participant’s eligibility to participate in the trial
  • For all trial participants: Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
  • For all trial participants: Clinically significant/symptomatic third space fluid accumulation (e.g. ascites or pleural effusion)
  • For Module 1: Women of childbearing potential. However, those women of childbearing potential who are not already pregnant or breastfeeding, or who agree to discontinue breastfeeding, or who meet the criteria listed in Protocol Section 5.1.4 clause 2 are considered eligible
  • For Module 1: Male patients with partners of childbearing potential or who are pregnant or breastfeeding. However, those patients who meet the criteria listed in Protocol Section 5.1.4 clause 3 are considered eligible
  • For all trial participants: Brain or leptomeningeal metastases
  • For Module 2: Women of childbearing potential. However, those women of childbearing potential who are not already pregnant or breastfeeding, or who agree to discontinue breastfeeding, or who meet the criteria listed in Protocol Section 5.1.5 clause 4 are considered eligible. Participants randomised to Module 2 Expansion Arm B do not need to adhere to the on-trial or post-trial contraception requirements
  • For Module 2: Male patients with partners of childbearing potential or who are pregnant or breastfeeding. However, those patients who meet the criteria listed in Protocol Section 5.1.5 clause 5 are considered eligible. Participants randomised to Module 2 Expansion Arm B do not need to adhere to the on-trial or post-trial contraception requirements
  • For all trial participants: Baseline corrected QTcF >450 ms measured on triplicate ECG (if an average QTcF of >450 ms then the patient is ineligible)
  • For all trial participants: Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase II trial of ginisortamab. Participation in an observational trial or interventional clinical trial that does not involve administration of an IMP and that would not place an unacceptable burden on the patient, in the opinion of the Investigator, would be acceptable

Where in Germany

Also in 2 other countries, 3 sites

  • Klinikum rechts der Isar der TU Muenchen AöRMunich, GermanyTaking people
  • Universitaetsklinikum Ulm AoRUlm, GermanyTaking people

About the trial

What the trial wants to find out

The primary objectives for Module 1 of the study are: 1. To assess the safety and toxicity profile of ginisortamab when given with SoC nab-paclitaxel and gemcitabine first-line therapy. 2. To identify a recommended dose of ginisortamab when given with SoC nab-paclitaxel and gemcitabine first-line therapy. 3. To document anti-tumour activity of ginisortamab when given with SoC nab-paclitaxel and gemcitabine first-line therapy.

Read full original descriptionShow less

The primary objectives for Module 2 of the study are: 1. To assess the safety and toxicity profile of ginisortamab when given in combination with cobimetinib as maintenance therapy. 2. To identify a recommended dose of ginisortamab when given in combination with cobimetinib as maintenance therapy. 3. To document possible anti-tumour activity of ginisortamab when given in combination with cobimetinib as maintenance therapy in participants with ongoing response or disease stabilisation after ≥16 weeks of a SoC regimen.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously I) with first-line standard of care nab-paclitaxel and gemcitabine, or II) in combination with MEK inhibitor maintenance therapy
Plain-language title
Tests ginisortamab with chemotherapy in advanced pancreatic cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
21 July 2026